Merrimack Reports Second Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P dip, trading choppy as tech stocks fall
- Brent hits lowest since before start of Iran war as more tankers exit Hormuz, easing supply
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- UBS Reiterates Buy Rating on Snowflake Inc. (SNOW)
Cowen Downgrades Merrimack Pharmaceuticals (MACK) to Market Perform
August 5, 2016 9:22 AM EDTCowen downgraded Merrimack Pharmaceuticals (NASDAQ: MACK) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on Merrimack Pharmaceuticals click here. For more ratings news on Merrimack Pharmaceuticals click here.
Shares of Merrimack Pharmaceuticals closed at $5.92 yesterday.
... More